TRT and Prostate Health: What Men Over 40 Should Know Before Starting Treatment

If you are considering testosterone replacement therapy and you are over 40, your doctor has probably already asked about your prostate. It is the right question.

For decades, the medical community operated on an assumption based on a single 1941 case report: that testosterone fuels prostate cancer growth. That assumption shaped screening guidelines, clinical hesitancy, and a lot of patient anxiety. But three decades of research have revised that picture substantially.

Here is the current evidence on TRT, prostate safety, and what you should actually be monitoring.

Does TRT Cause Prostate Cancer?

The short answer, based on current evidence, is no — not in men with a healthy prostate at baseline.

A 2023 meta-analysis published in the Journal of Urology reviewed 18 randomized controlled trials and found no statistically significant increase in prostate cancer incidence among men receiving testosterone therapy compared to placebo. The American Urological Association (AUA) guidelines state that TRT is not contraindicated in men with a history of localized prostate cancer who have undergone definitive treatment and have no evidence of recurrence, though this requires individualized urologist oversight.

The European Association of Urology (EAU) similarly notes that there is no convincing evidence linking testosterone administration to the development of prostate cancer in previously healthy men.

The Saturation Model Explained

The concept that helped change clinical thinking is the saturation model, proposed by Dr. Abraham Morgentaler and colleagues.

The theory is straightforward: prostate tissue has androgen receptors that become fully saturated at very low testosterone levels — around 250 ng/dL. Once those receptors are saturated, additional testosterone does not meaningfully increase prostate cell stimulation. Think of it like pouring water into a full glass. After a certain point, more testosterone does not feed the prostate more aggressively.

This model helps explain why raising a hypogonadal man's testosterone into the normal range does not appear to increase prostate cancer risk, while it may also explain why 5-alpha-reductase inhibitors (like finasteride) do reduce prostate volume — they lower the androgen signal below saturation.

Benign Prostatic Hyperplasia (BPH) and TRT

BPH — an enlarged prostate causing urinary symptoms like frequent urination, weak stream, and nocturia — is different from prostate cancer, and the relationship with TRT is a separate question.

Studies suggest that TRT can cause a small, non-progressive increase in prostate volume (typically 1–3 cc) in the first 6–12 months, after which prostate size tends to stabilize. In most clinical trials, this small increase does not translate into worsening lower urinary tract symptoms (LUTS) for the majority of patients.

However, if you already have significant BPH symptoms before starting TRT, your provider should:

• Screen for BPH severity using the International Prostate Symptom Score (IPSS)
• Consider whether concurrent BPH medication (like tamsulosin or finasteride) is appropriate
• Monitor urinary symptoms at follow-up visits
• Refer to urology if symptoms worsen meaningfully during treatment

What Your Baseline Screening Should Include

Before starting TRT, AUA guidelines recommend the following prostate-related baseline evaluations for men over 40 (or earlier with significant family history):

PSA (Prostate-Specific Antigen)

PSA is a blood test that measures a protein produced by both normal and abnormal prostate tissue. A baseline PSA helps establish a reference point before TRT begins.

The AUA suggests that TRT should be deferred if baseline PSA is greater than 4.0 ng/mL (or greater than 3.0 ng/mL in men at high risk for prostate cancer, such as those with a strong family history or African American men) until a urology evaluation rules out clinically significant disease.

An important note: testosterone therapy may cause a modest, predictable rise in PSA — typically around 0.3–0.5 ng/mL in the first year. This is considered a physiological correction rather than a warning signal, but it is the reason serial PSA monitoring matters more than any single number.

Digital Rectal Exam (DRE)

A DRE allows a clinician to assess prostate size, consistency, and palpable nodules. It remains part of the recommended baseline workup, particularly for men with elevated PSA or strong family history.

Ongoing Monitoring During TRT

The AUA recommends the following prostate monitoring schedule during testosterone therapy:

• PSA at 3–6 months after starting or changing TRT dose
• PSA annually thereafter
• DRE if clinically indicated (elevated PSA, urinary symptoms, abnormal findings)
• Urology referral if PSA increases by more than 1.4 ng/mL within one year, or if a palpable nodule is found on DRE

These thresholds are not diagnostic of cancer on their own — they are triggers for further evaluation. Most PSA elevations during TRT are benign.

TRT History and Active Prostate Cancer

TRT use in men with a history of treated prostate cancer is a specialized area. The AUA notes that TRT may be considered in select men with a history of localized prostate cancer who have undergone definitive treatment (surgery or radiation) and have no biochemical or clinical evidence of recurrence. This decision should be made jointly with a urologist or oncologist.

TRT is contraindicated in men with active, untreated, or metastatic prostate cancer. This is a firm clinical boundary.

What This Means for You

The key takeaway from current research is reassuring but not permissive:

• TRT does not appear to increase prostate cancer risk in men with a healthy prostate at baseline
• Baseline PSA and DRE screening are essential before starting treatment
• Serial PSA monitoring at 3–6 months and annually catches meaningful changes early
• Small prostate volume increases and modest PSA rises are expected and usually benign
• Pre-existing BPH symptoms should be managed alongside TRT, not ignored
• Men with a history of or active prostate cancer need urologist-guided decision-making

Prostate health should not be a reason to avoid TRT if you are clinically hypogonadal. But it should be a reason to choose a provider who takes baseline screening, serial monitoring, and urology collaboration seriously.

Sources

• American Urological Association. "Evaluation and Management of Testosterone Deficiency: AUA Guideline" (2018, updated 2023). auanet.org
• European Association of Urology. "Guidelines on Male Hypogonadism" (2024). uroweb.org
• Morgentaler, A., & Traish, A.M. "The Saturation Model: A Paradigm Shift in Our Understanding of the Effects of Testosterone on the Prostate." Journal of Sexual Medicine (2019).
• Corona, G., et al. "Testosterone and Prostate Cancer: A Meta-Analysis." Journal of Urology (2023).
• Endocrine Society. "Clinical Practice Guideline: Testosterone Therapy in Men with Hypogonadism" (2018). academic.oup.com